<DOC>
	<DOC>NCT01587586</DOC>
	<brief_summary>Primary objectives: The purpose of this study is to determine and compare the sustained virologic response (SVR, undetectable HCV RNA at Follow up week 24 (FW24)) across treatment groups. To determine and compare the safety and tolerability of P1101 + Ribavirin across treatment groups.</brief_summary>
	<brief_title>Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With HCV Genotype 1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adults ≥18 years of age ( ≥20 years for subjects enrolled in Taiwan); Confirmed diagnosis of chronic hepatitis C (CHC) virus genotype 1 infection; Compensated liver disease: with normal or elevated ALT/AST, no evidence of cirrhosis or portal hypertension as identified by ultrasound or any other procedures within 6 months before study entry; Treatment naïve No other form of chronic liver disease apart from chronic hepatitis C infection; Hematology and renal biochemistry should be in definded ranges; Be able to attend all scheduled visits and to comply with all study procedures; Be able to provide written informed consent. Positive test for hepatitis B surface antigen (HBsAg) or human immunodeficiency virus (HIV) at screening; Pregnancy or, in women of childbearing potential or in spouses of such women, unwillingness or inability to practice adequate contraception; Inability to comprehend the written consent form;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Hepatitis C, Chronic</keyword>
	<keyword>Interferon-alpha</keyword>
	<keyword>Hepatitis C Virus</keyword>
</DOC>